Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

Table 2

Immune phenotype over the course of the GRACE immunology substudy.

Median (range)	Baseline		Wk 12		Wk 48
	All^a	Suppressed^b	All^a	Suppressed^b	All^a	Suppressed^b
CD4+ (%)	15 (1, 33)	15 (1, 33)	16 (2, 36)	17 (2, 36)	21 (3, 40)	21 (5, 40)
CD8+ (%)	60.5 (39, 83)	62 (42, 83)	59 (35, 84)	55 (36, 84)	50 (27, 87)	49 (27, 87)
CD4+/CD8+ ratio (%)	0.22 (0.01, 0.70)	0.22 (0.01, 0.70)	0.30 (0.03, 1.00)	0.36 (0.03, 1.00)	0.41 (0.04, 1.21)	0.52 (0.08, 1.21)
CD4+/CD38+/DR+ (%)	22.5 (10, 88)	22 (10, 88)	19 (9, 76)	18 (9, 53)	13 (2, 36)	11 (2, 36)
CD8+/CD38+/DR+ (%)	48.5 (18, 76)	47 (18, 76)	36.5 (11, 71)	34 (11, 62)	25 (4, 68)	22 (4, 52)
CD4+/CD95+ (%)	15 (1, 35)	16 (1, 35)	21 (3, 38)	22 (3, 38)	23 (4, 41)	24 (6, 41)
CD8+/CD95+ (%)	71.5 (40, 87)	70 (40, 87)	69.5 (44, 88)	66 (44, 88)	55 (32, 80)	49 (32, 79)
CD3+/CD4+/CD28+ (%)	93 (46, 99)	95 (56, 99)	94 (67, 100)	94 (70, 100)	96 (67, 99)	96 (67, 99)
CD3+/CD8+/CD28+ (%)	59.5 (39, 86)	62 (39, 85)	50 (39, 79)	50.5 (39, 79)	56 (23, 82)	56 (35, 82)

^a𝑛=32 at baseline, 𝑛=30 at Wk 12 and 𝑛=25 at Wk 48; ^bHIV-RNA < 50 copies/mL at Wk 48 (or at Wks 36 and 52 if a Wk 48 sample was not available), 𝑛=19.